Results 11 to 20 of about 918 (92)

Averaging of absorbed doses: How matter matters

Medical Physics, Volume 50, Issue 10, Page 6600-6613, October 2023., 2023
Abstract Background Dosimetry in radionuclide therapy often requires the calculation of average absorbed doses within and between spatial regions, for example, for voxel‐based dosimetry methods, for paired organs, or across multiple tumors. Formation of such averages can be made in different ways, starting from different definitions. Purpose The aim of
Johan Gustafsson, Michael Ljungberg, Gudrun Alm Carlsson, Erik Larsson, Carl Fredrik Warfvinge, Pernilla Asp, Katarina Sjögreen Gleisner   +6 more
wiley   +1 more source

Accuracy and precision of few-time-points renal dosimetry for [¹⁷⁷Lu]Lu-PSMA-617 therapy: Analysis with nonlinear mixed-effects modeling. [PDF]

Med Phys
Abstract Background Determination of time‐integrated activity (TIA) with a reduced number of imaging sessions is essential for minimizing patient burden and clinical workload in the dosimetry of [177Lu]Lu‐PSMA‐617. One approach to achieve this is by performing single‐time‐point (STP) dosimetry.
Hakim AR, Hardiansyah D, Yousefzadeh-Nowshahr E, Nemer U, Ritawidya R, Kind F, Beer AJ, Meyer PT, Glatting G, Mix M.   +9 more
europepmc   +2 more sources

Advances in macrocyclic chelators for positron emission tomography imaging

VIEW, Volume 4, Issue 5, October 2023., 2023
Bifunctional chelators play a key role in radiometal‐based radiopharmaceuticals, affecting the labeling, targeting, and pharmacokinetics of bioconjugations and ensuring the stable complexation of the metal in vivo. The macrocycles have the capacity to form complexes with extremely high thermodynamics, kinetics, and stability compared to acyclic ...
Mengting Li, Sheng Wang, Qunshou Kong, Xinyi Cheng, Huanhuan Yan, Yao Xing, Xiaoli Lan, Dawei Jiang   +7 more
wiley   +1 more source

Relationship Between Best Tumor Shrinkage and Progression-Free Survival and Overall Survival in Patients With Progressive Midgut Neuroendocrine Tumors Treated With [¹⁷⁷Lu]Lu-DOTA-TATE: Ad Hoc Analysis of the Phase III NETTER-1 Trial. [PDF]

Cancer Med
We analyzed data from the phase III NETTER‐1 study of 177Lu‑DOTATATE for patients with advanced midgut neuroendocrine tumors to explore whether tumor shrinkage is associated with durable efficacy. Although patients receiving 177Lu‑DOTATATE had a progression‐free survival (PFS) benefit, no obvious association between best tumor shrinkage and PFS or ...
Pavel M, Caplin ME, Ruszniewski P, Hertelendi M, Krenning EP, Strosberg JR, NETTER‐1 Study Group.   +6 more
europepmc   +2 more sources

Molecular theranostics: principles, challenges and controversies

Journal of Medical Radiation Sciences, Volume 72, Issue 1, Page 156-164, March 2025.
Molecular theranostics offers a powerful tool to drive precision medicine in nuclear oncology. While theranostics is not a new principle in nuclear medicine, recent advances in instrumentation and radiopharmacy have driven a reinvigoration and a broader suite of applications.
Geoffrey Currie
wiley   +1 more source

Gold Nanoparticles Loaded With Lutetium‐177 Labeled DOTA‐TATE Exhibit Superior AR42J Cell Affinity and Extended Blood Circulation in AR42J Tumor Xenografts

Nano Select, Volume 7, Issue 2, February 2026.
The present study reports the development of a gold nanoparticle‐based delivery system functionalized with the established radiopharmaceutical [177Lu]Lu‐DOTA‐TATE. This design aims to enhance tumor‐targeting efficacy and improve the overall in vivo pharmacokinetic profile. In vitro studies demonstrated enhanced specificity toward somatostatin receptor (
Dheeraj Kumar, Rani Gnanasekar, Sheela Muralidharan, Shubhangi Mirapurkar, Krishna Mohan Repaka, Anupam Mathur, Madhava B. Mallia   +6 more
wiley   +1 more source

Advances in radiopharmaceuticals for cancer radiotheranostics: CCK2R targeting as a paradigm for translational innovation

Cancer Communications, Volume 45, Issue 11, Page 1431-1455, November 2025.
Abstract Radiopharmaceuticals are reshaping the landscape of cancer therapy, offering a unique theranostic advantage that is becoming increasingly central to precision medicine. By labeling the same molecular scaffold with different radionuclides, these agents enable seamless integration of diagnostic imaging and targeted therapy.
Jing Li, Xuejun Wen, Rebeka Rita Reszegi, Hemavarshini Kamalrhaj, Wolfgang J. Parak, Xiaoyuan Chen, Jingjing Zhang   +6 more
wiley   +1 more source

Glucagonoma and Glucagonoma Syndrome: An Updated Review

Clinical Endocrinology, Volume 103, Issue 4, Page 417-426, October 2025.
ABSTRACT Background Glucagonoma is a rare well‐differentiated slowly proliferating pancreatic neuroendocrine tumour, characterized by several manifestations including necrolytic migratory erythema, weight loss, diabetes and anaemia. Aim The purpose of the current review was to acknowledge literature about this rare tumour discerning the clinical ...
Sofia Anelli, Rossella Mazzilli, Virginia Zamponi, Beatrice Giorgini, Bianca Golisano, Camilla Mancini, Flaminia Russo, Francesco Panzuto, Antongiulio Faggiano   +8 more
wiley   +1 more source

Peptide‐Drug Conjugates: A New Hope for Cancer

Journal of Peptide Science, Volume 31, Issue 8, August 2025.
Peptide‐drug conjugates (PDCs) are emerging cancer therapeutics inspired by antibody‐drug conjugates, offering targeted delivery via peptide ligands. Despite structural versatility, challenges like instability and rapid clearance hinder clinical progress.
Amy Armstrong, Fleur Coburn, Yanyamba Nsereko, Othman Al Musaimi   +3 more
wiley   +1 more source

Radiolabeled Nanogels: From Multimodality Imaging to Combination Therapy of Cancer

Small Science, Volume 5, Issue 8, August 2025.
Nanogel refers to nanosized particles formed by physical or chemical crosslinking of polymers. Rational design and refinement of nanogel properties are imperative to unlock their full potential, ensuring tailored solutions for personalized cancer management. This review elucidates the transformative potential of radiolabeled nanogels in revolutionizing
Sanchita Ghosh, Weibo Cai, Rubel Chakravarty   +2 more
wiley   +1 more source